Effect of drug intervention on hypertensive patients
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2019/11/021961
- Lead Sponsor
- All India Institute of medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients of either sex aged between 30 â?? 65 years.
Hypertensive patients who had not achieved target BP levels as defined by JNC 8 with monotherapy for at least one month
Willing to participate by giving written informed consent.
Hypertensive patients with other comorbidities
Patients diagnosed with secondary hypertension
Patients of hypertensive emergency and hypertensive urgency
Presence of hyperkalaemia (potassium level >= 5.5 mEq)
Pregnant and lactating women
•Patient history of allergic to Azilsartan, Telmisartan, and Amlodipine
Any serious hepatic, cardiovascular, renal or pulmonary condition which may prevent participation in the study
Any drug having an adverse interaction with azilsartan, telmisartan, and amlodipine in term of safety and efficacy.
Patients diagnosed with Type 1 DM.
Type 2 Diabetic patients with HbA1c > 8.5%
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate and compare the response rate of azilsartan and amlodipine against telmisartan and amlodipine after 12 weeks of therapy <br/ ><br> <br/ ><br>Timepoint: To evaluate and compare the response rate of azilsartan and amlodipine against telmisartan and amlodipine after 12 weeks of therapy <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method To evaluate and compare the change in blood pressure from baseline at 12 weeks in both the groups <br/ ><br>To evaluate and compare the changes in NT- pro BNP level, cystatin c & highly sensitive Troponin I(hsTnI) from baseline at 12 weeks <br/ ><br>To evaluate and compare the changes in BUN, serum urea,creatinine from baseline at 12 weeks <br/ ><br>To compare adverse effects of the two treatment population <br/ ><br> <br/ ><br>Timepoint: 12 weeks